The Company
EnlightenVue has developed a novel single-use, 2mm micro endoscope platform (surgiVue™) with an expandable tip and two working channels. 510(k) cleared, with broad multispecialty labeling across hepatobiliary, pulmonary, urology, ENT, and vascular applications.
What Cicada Did
Sharpened the positioning for the surgiVue™ platform. Built the executive summary for the conference circuit. Ran targeted investor outreach across family offices, strategic investors, and growth equity heading into the seed round, building and activating the pipeline in parallel with the pitch.
The Outcome
A high-quality, multi-channel investor pipeline established coming out of LSI 2026 to support continued commercialization and the path to Series A.
The Company
EpiWatch is the first and only FDA-cleared seizure detection app for Apple Watch. Running passively on the watch and iPhone, it detects tonic-clonic seizures and alerts caregivers in real time, helping reduce the risk of injury and SUDEP. Clearance changed the company's entire commercial problem: it had spent years recruiting patients into clinical trials, and now needed to sell a prescription consumer product to families.
What Cicada Did
Migrated the site off Squarespace and rebuilt it as a conversion-ready consumer experience, repositioned around FDA-cleared status rather than trial enrollment, with distinct pathways for patients, caregivers, and prescribing clinicians. Stood up the measurement layer and CRM so app downloads, waitlist signups, and prescription submissions could be tracked as one funnel, then built the nurture and onboarding email automations behind it. Cicada now runs an ongoing creative testing and paid social program, developing video and caregiver creative against a defined cost per prescription target.
The Outcome
A prescription funnel that runs end to end, from first ad impression through prescription validation and activation, with paid social growing to roughly half of all site traffic. The repositioned site now carries published Phase III results, App Store distribution, and twelve advocacy partner organizations. Cicada remains engaged across brand, demand generation, and sales enablement.
The Company
Conformal Medical is a clinical-stage Class III medical device company operating in the electrophysiology and cardiology space. Following a successful $35 million Series D round, the company needed to accelerate clinical site engagement and build durable KOL presence ahead of commercialization.
What Cicada Did
Engaged post-Series D to support outbound communication strategy across email, social media, and electrophysiology and cardiology channels. Established KOL presence in industry publications and events. Supporting infrastructure for the active trial app, and implementing a unified CRM platform for site-lead engagement and tracking.
The Outcome
Active clinical trial infrastructure in place with full CRM visibility into site-lead engagement. Electrophysiology KOL program underway across publications and conference channels.
The Company
CustomSurg is a Zurich-based Harvard and ETH Zurich deep tech venture in orthopedics. Its OrthoPlanner™ platform turns a CT scan into a surgical plan, solving the fracture realignment in 3D and delivering the recommended implant configuration to the surgeon before the case begins. When Cicada was engaged, the company was pre-commercial in the US, with strong clinical validation and deep surgeon relationships but no infrastructure to convert that goodwill into a trackable pipeline.
What Cicada Did
Built a physician-facing website and supporting CRM in parallel on a six-week timeline. Shipped a four-page architecture organized around the surgeon's decision path, with "Send a Case" as the single primary CTA and forms throughout, built so every inbound intent lands in the CRM by default. Stood up a GDPR-compliant CRM with properties mapped to real sales intent, then migrated five years of scattered surgeon engagement history, including conference rosters and the KOL outreach tracker, into one system.
The Outcome
Live on the go-live date set at kickoff, with site and CRM operating as one funnel. Five years of surgeon relationship history consolidated into a single source of truth on the clinical pipeline, structured for German-language rollout so US market entry and DACH expansion run on the same infrastructure. The commercial engine was standing before regulatory clearance arrived.
Join the healthcare innovators who've trusted Cicada to bring their technology to market. Let's see if we're a fit.
Schedule a Call